+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

North America Biopharmaceutical Contract Manufacturing Market to 2027 - Regional Analysis and Forecasts by Product; Service, and Geography

  • PDF Icon

    Report

  • 133 Pages
  • April 2020
  • Region: North America
  • The Insight Partners
  • ID: 5028605
UP TO OFF until Sep 30th 2023
North America, the biopharmaceutical contract manufacturing market, is anticipated to reach US$ 11,754.24 Mn in 2027 from US$ 6,202.70 Mn in 2019. The market is projected to grow with a CAGR of 8.5% from 2020-2027.

The biopharmaceutical contract manufacturing market is growing primarily due to the increasing outsourcing by pharmaceutical companies and increasing demand for biologics in the North America region that are boosting the market over the years. Restraining factors, such as increasing competition in the industry likely to damage the growth of the market in the coming years. Additionally, robust advancements in research and development activities and consolidation in the pharmaceutical CMO industry are likely to increase the growth of the biopharmaceuticals contract manufacturing in the forecast period.

Contract manufacturing is the type of outsourcing where a company enters into an agreement or legal settlement with another manufacturing firm for products, parts, or components, which the former will then use in its production process to complete its product. The various biopharmaceutical companies manufacture antibodies, non-antibody scaffolds, recombinant proteins, fragments as well as DNA from different sources.

The contract manufacturing organization (CMO) offers numerous benefits to pharmaceutical companies, including reducing investments in facilities, drug development costs, thereby improves net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows pharmaceutical and biotechnology companies to redirect resources to other areas. A few years ago, the CMO industry was a niche service market, offering additional manufacturing capacity or specific services to pharmaceutical companies.

Moreover, many pharmaceutical companies are refocusing on their core capabilities such as research and development, leading to divestments of in-house manufacturing capacities, which is growing reliance on CMOs for manufacturing. Furthermore, CMOs play crucial roles in providing additional capacities to mitigate the risk of supply shortages by offering additional sites for pharmaceutical companies with multisite supply strategies as well as backup capacities. Catalent Pharma Solutions announced it completed a $5.5 million expansion program at its 200,000 square foot site in Philadelphia, Penn., to provide additional clinical packaging and storage capacity. The expansion not only allows us to meet the demand for additional capacity to serve large-scale clinical studies today but also provides the space necessary for future growth. Thus, owing to the factors mentioned above are likely to boost the growth of the biopharmaceutical contract manufacturing market in North America during the forecast period.

In 2019, the biologics segment accounted for the largest market share in the biopharmaceutical contract manufacturing market in North America. The growth of biologics is attributed due to the enormous commercial success of biologics, which is described through the existence of a large number of FDA-approved biologics in the market. However, biologics manufacturers strive to reduce manufacturing cost, deliver high-quality drugs, improve process efficiency, and accelerate market entry. CMOs can adopt as per requirement and help in process innovation and improve operational efficiency.

In 2019, the analytical and quality control segment estimated the highest CAGR in the market during the forecast period. CMOs provide a wide array of services ranging from cell cultivation to final product packaging. Increasing regulatory compliance, complex manufacturing process, and product integrity are driving the adoption of the services mentioned above offered by CMOs. Hence, the segment is anticipated to witness growth at a significant rate during the forecast period.

Some of the significant secondary sources for cold plasma equipment included in the report are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA).

Reasons to Buy
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America biopharmaceutical contract manufacturing market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America biopharmaceutical contract manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 North America Biopharmaceutical Contract Manufacturing Market - By Product
1.3.2 North America Biopharmaceutical Contract Manufacturing Market - By Service
1.3.3 North America Biopharmaceutical Contract Manufacturing Market - By Country
2. North America Biopharmaceutical Contract Manufacturing Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Biopharmaceutical Contract Manufacturing Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 4.2.1 Biopharmaceutical Contract Manufacturing Market - North America PEST Analysis
4.3 Expert Opinion
5. North America Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increasing Outsourcing by Pharmaceutical Companies
5.1.1 Increasing Demand of Biologics
5.2 Key Restraints
5.2.1 Increasing Competition in the Industry
5.3 Key Market Opportunities
5.3.1 Robust advancements in research and development activities
5.4 Future Trend
5.4.1 Consolidation in Pharmaceutical CMO Industry
5.5 Impact Analysis
6. Biopharmaceutical Contract Manufacturing Market - North America Analysis
6.1 North America Biopharmaceutical Contract Manufacturing Market Revenue Forecasts and Analysis
7. North America Biopharmaceutical Contract Manufacturing Market Analysis And Forecasts To 2027 - By Product
7.1 Overview
7.2 North America Biopharmaceutical Contract Manufacturing Market, By Product 2019 & 2027 (%)
7.2.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecasts to 2027, By Product (US$ Mn)
7.3 Biologics
7.3.1 Overview
7.3.2 North America Biologics Market Revenue and Forecast to 2027 (US$ Mn)
7.3.3 Monoclonal Antibodies
7.3.3.1 Overview
7.3.3.2 North America Monoclonal Antibodies Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.4 Recombinant Proteins
7.3.4.1 Overview
7.3.4.2 North America Recombinant Proteins Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.5 Vaccines
7.3.5.1 Overview
7.3.5.2 North America Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.6 Others
7.3.6.1 Overview
7.3.6.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Biosimilars
7.4.1 Overview
7.4.2 North America Biosimilars Market Revenue and Forecast to 2027 (US$ Mn)
8. North America Biopharmaceutical Contract Manufacturing Market Analysis - By Service
8.1 Overview
8.2 North America Biopharmaceutical Contract Manufacturing Market, By Service 2019-2027 (%)
8.2.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecasts to 2027, By Service (US$ Mn)
8.3 Development Process
8.3.1 Overview
8.4 North America Development Process Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Final Dosage Operation
8.5.1 Overview
8.6 North America Final Dosage Operation Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Analytical and Quality Control
8.7.1 Overview
8.7.2 North America Analytical and Quality Control Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Final Packaging
8.8.1 Overview
8.8.2 North America Final Packaging Market Revenue and Forecasts to 2027 (US$ Mn)
9. Biopharmaceutical Contract Manufacturing Market Revenue and Forecasts To 2027 - Geographical Analysis
9.1 North America Biopharmaceutical Contract Manufacturing Market Revenue and Forecasts To 2027
9.1.1 Overview
9.1.2 North America: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.3 North America: Biopharmaceutical Contract Manufacturing Market, by Product, 2018-2027 (USD Million)
9.1.3.1 North America: Biologics Market, by Type, 2018-2027 (USD Million)
9.1.4 North America: Biopharmaceutical Contract Manufacturing Market, by Service, 2018-2027 (USD Million)
9.1.5 North America: Biopharmaceutical Contract Manufacturing Market, by Country, 2019 & 2027 (%)
9.1.6 US: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.1 US: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.2 US: Biopharmaceutical Contract Manufacturing Market, by Product, 2018-2027 (USD Million)
9.1.6.2.1 US: Biologics Market, by Type, 2018-2027 (USD Million)
9.1.6.3 US: Biopharmaceutical Contract Manufacturing Market, by Service, 2018-2027 (USD Million)
9.1.7 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.1 Canada: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.2 Canada: Biopharmaceutical Contract Manufacturing Market, by Product, 2018-2027 (USD Million)
9.1.7.2.1 Canada: Biologics Market, by Type, 2018-2027 (USD Million)
9.1.7.3 Canada: Biopharmaceutical Contract Manufacturing Market, by Service, 2018-2027 (USD Million)
9.1.8 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.1 Mexico: Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.2 Mexico: Biopharmaceutical Contract Manufacturing Market, by Product, 2018-2027 (USD Million)
9.1.8.2.1 Mexico: Biologics Market, by Type, 2018-2027 (USD Million)
9.1.8.3 Mexico: Biopharmaceutical Contract Manufacturing Market, by Service, 2018-2027 (USD Million)
10. Impact of COVID-19 Pandemic on North America Biopharmaceutical Contract Manufacturing Market
10.1 North America: Impact assessment of COVID-19 Pandemic
11. North America Biopharmaceutical Contract Manufacturing Market Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 THERMO FISHER SCIENTIFIC INC.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 General Electric Company
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Lonza
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Samsung Biologics.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 AbbVie Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Lonza Group AG
  • Boehringer Ingelheim International GmbH
  • Inno Biologics Ventures Sdn Bhd
  • Thermo Fisher Scientific
  • AbbVie Inc.
  • WuXi Biologics
  • General Electric
  • Samsung Biologics
  • Merck KGaA
  • Ajinomoto Co., Inc